Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb;15(2):112-6.
doi: 10.3779/j.issn.1009-3419.2012.02.09.

[EML4-ALK fusion gene in lung cancer and its biological function]

[Article in Chinese]
Tong Yang  1 , Hongyu Liu, Jun Chen
Affiliations
Review

[EML4-ALK fusion gene in lung cancer and its biological function]

[Article in Chinese]
Tong Yang et al. Zhongguo Fei Ai Za Zhi. 2012 Feb.

Erratum in

  • Zhongguo Fei Ai Za Zhi. 2012 Nov 20;15(11):671
No abstract available

PubMed Disclaimer

Figures

1
1
EML4-ALK融合基因形成示意图 Schematic representation of fusion junctions and flanking sequences of the EML4-ALK fusion gene. Fusion of the N-terminal portion of EML4 (comprising the basic region, the HELP domain and part of the WD-repeat region) to the intracellular region of ALK (containing the tyrosine kinase domain).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Souquet PJ, Chauvin F, Boissel JP, et al. Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. http://www.sciencedirect.com/science/article/pii/0169500295004309 Lung Cancer. 1995;(12 Suppl 1):147–154. - PubMed
    1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98. doi: 10.1056/NEJMoa011954. - DOI - PubMed
    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi: 10.1056/NEJMoa0810699. - DOI - PubMed
    1. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)[corrected] J Clin Oncol. 2003;21(12):2237–2246. doi: 10.1200/JCO.2003.10.038. - DOI - PubMed
    1. Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. http://www.sciencedirect.com/science/article/pii/S0093775402000325 Semin Oncol. 2003;30(1 Suppl 1):30–38. - PubMed

Publication types

MeSH terms

Substances